Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer

Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor 2 (HER2), has shown activity in combination with capecitabine in patients with HER2-positive advanced breast cancer progressive on standard treatment regimens. We present results on preapproval drug access for this comb...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Netherlands journal of medicine 2010-09, Vol.68 (9), p.371-376
Hauptverfasser:	Kroep, J R, Linn, S C, Boven, E, Bloemendal, H J, Baas, J, Mandjes, I A M, van den Bosch, J, Smit, W M, de Graaf, H, Schröder, C P, Vermeulen, G J, Hop, W C J, Nortier, J W R
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - mortality Capecitabine Confidence Intervals Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Female Fluorouracil - analogs & derivatives Fluorouracil - therapeutic use Health Status Indicators Humans Kaplan-Meier Estimate Middle Aged Multivariate Analysis Prognosis Proportional Hazards Models Protein Kinase Inhibitors - therapeutic use Protein-Tyrosine Kinases - antagonists & inhibitors Quinazolines - therapeutic use Receptor, ErbB-2 - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!